Fig. 7

Overexpression of miR-499a inhibits TGFβ-induced resistance in vitro and in vivo. a With increasing concentrations of erlotinib from 0.03 to 3 μmol/L, the percentage of viable cells of CD166⁺ OSCs infected with Lv-miR-499a, Lv-NC, si-SHKBP1 or si-NC were measured by MTT. Note: Columns, mean of three individual experiments; SD,**, P < 0.01. b Western-blotting was used with antibodies specific for Snail, Twist, and ZEB1 in CD166⁺ OSCs with or without infection of Lv-miR-499a. GAPDH was used as the control. c RNA was extracted from 5 OS directly xenografted tumors Levels of miR-499a were measured by qPCR. Note: Columns, mean of three individual experiments; SD,**, P < 0.01. d The potential of tumor initiation of CD166⁺ OSCs, Lv-NC-OSCs and si-SHKBP1- OSCs fractions by subcutaneous injection, and representative tumor volumes were measured following treatment with or without three cycles of erlotinib. Note: Columns, mean of three individual experiments; SD,**, P < 0.01